Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
about
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Activity and safety of crizoti ...... phase II trial 90101 'CREATE'.
@en
Activity and safety of crizoti ...... phase II trial 90101 'CREATE'.
@nl
type
label
Activity and safety of crizoti ...... phase II trial 90101 'CREATE'.
@en
Activity and safety of crizoti ...... phase II trial 90101 'CREATE'.
@nl
prefLabel
Activity and safety of crizoti ...... phase II trial 90101 'CREATE'.
@en
Activity and safety of crizoti ...... phase II trial 90101 'CREATE'.
@nl
P2093
P2860
P50
P356
P1433
P1476
Activity and safety of crizoti ...... phase II trial 90101 'CREATE'.
@en
P2093
A Anthoney
J Sufliarsky
L Collette
L H Lindner
M Debiec-Rychter
P Reichardt
P Schöffski
P2860
P304
P356
10.1093/ANNONC/MDX527
P577
2017-09-18T00:00:00Z